Atezolizumab

The FDA expanded the approval of atezolizumab to include first-line monotherapy of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression.

Atezolizumab in combination with bevacizumab improved OS and PFS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study published in The New England Journal of Medicine.

Treatment with the anti-PD-L1 antibody atezolizumab after the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel appeared safe and clinically effective for refractory diffuse large B cell lymphoma, according to phase 2 results of the ZUMA-6 trial presented at the virtual American Association for Cancer Research Annual Meeting.

Atezolizumab plus cobimetinib significantly prolonged PFS compared with atezolizumab alone among a cohort of patients with advanced biliary tract cancer, according to results of a phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.

Atezolizumab in combination with enzalutamide did not extend OS compared with enzalutamide monotherapy among men with metastatic castration-resistant prostate cancer, according to results of a randomized phase 3 IMbassador250 study presented at the virtual American Association for Cancer Research Annual Meeting.

The addition of atezolizumab to cobimetinib and vemurafenib significantly prolonged PFS and conferred durable responses among patients with BRAF V600 mutation-positive advanced melanoma, according to results of the randomized phase 3 IMspire150 study presented at the virtual American Association for Cancer Research Annual Meeting.

Today is Triple-Negative Breast Cancer Awareness Day.

The FDA granted priority review to atezolizumab monotherapy as first-line treatment for patients with advanced nonsquamous or squamous non-small cell lung cancer without EGFR or ALK mutations and with high PD-L1 expression, according to a press release from the agent’s manufacturer.

Adjuvant atezolizumab failed to extend DFS compared with observation among patients with muscle-invasive urothelial cancer, according to topline results of a randomized phase 3 trial released by the agent’s manufacturer.

Atezolizumab in combination with bevacizumab delayed time to deterioration of quality of life, physical functioning and role functioning compared with standard-of-care sorafenib as first-line treatment for unresectable hepatocellular carcinoma, according to patient-reported outcomes of the randomized phase 3 IMbrave 150 study scheduled for presentation at Gastrointestinal Cancers Symposium.